Focus on Acute Pain and Uremic Pruritus

Cara Banks $15M for Pursuit of Nonaddictive Pain Drug, by Donna Young (BioWorld Today) The $15 million Series D financing Cara Therapeutics Inc. closed this week will go a long way toward advancing the development of its peripherally restricted kappa opioid agonist CR845, said CEO Derek Chalmers...

Phase 3 safety extension trial underway

$2.5M Milestones Earned for Advancement of CR845 in Phase 2 Clinical Trials in U.S. and Japan SHELTON, Conn. , Oct. 13, 2015 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (NASDAQ:CARA), a biotechnology company focused on developing and commercializing new chemical entities designed to alleviate pain

Cara receives upfront payment of $50 million in cash and an equity investment of $20 million Cara eligible for up to $470 million in regulatory and commercial milestones VFMCRP to commercialize KORSUVA injection worldwide except in the U.S., Japan and South Korea Cara to commercialize KORSUVA

Statistically significant improvement in primary endpoint of proportion of patients with three point or greater reduction in mean Worst Itching Intensity NRS score vs. placebo (p=0.02) - Statistically significant improvement in key secondary endpoint of proportion of patients with four point or

SHELTON, Conn. , Dec. 18, 2014 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq:CARA), a biotechnology company focused on developing and commercializing new chemical entities designed to selectively target peripheral kappa opioid receptors, today announced that it has been selected for addition

SHELTON, Conn. , Dec. 2, 2014 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq:CARA), a biopharmaceutical company focused on developing and commercializing new chemical entities designed to alleviate pain and pruritus by selectively targeting kappa opioid receptors, today announced the

Experienced Pain Drug Developer and Expert in Human Abuse Liability to Lead Clinical Development of CR845 for the Treatment of Acute and Chronic Pain